{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:01:55Z","timestamp":1782853315570,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.05.026","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:33:53Z","timestamp":1656092033000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer"],"prefix":"10.1016","volume":"172","author":[{"given":"Pietro","family":"Rosellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Amintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Caumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigol\u00e8ne","family":"Galland-Girodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cuguilli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-0657","authenticated-orcid":false,"given":"Charlotte","family":"Domblides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-1833","authenticated-orcid":false,"given":"Amandine","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-0850","authenticated-orcid":false,"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-1928","authenticated-orcid":false,"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-9711","authenticated-orcid":false,"given":"Pierre-Olivier","family":"Girodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.05.026_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.05.026_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.05.026_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.05.026_bib6","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.05.026_bib7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib8","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.026_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.026_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.026_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.05.026_bib15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.05.026_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fonc.2019.01161","article-title":"The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.05.026_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.05.026_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.05.026_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.lungcan.2019.05.015","article-title":"Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes","volume":"133","author":"Aredo","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nature09571","article-title":"Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells","volume":"468","author":"Nakada","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.026_bib22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1097-2765(01)00258-1","article-title":"The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death","volume":"7","author":"Karuman","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejca.2022.05.026_bib23","doi-asserted-by":"crossref","first-page":"R383","DOI":"10.1016\/j.cub.2004.05.012","article-title":"LKB1 kinase: master and commander of metabolism and polarity","volume":"14","author":"Spicer","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/j.ejca.2022.05.026_bib24","first-page":"3659","article-title":"Inactivation of LKB1\/STK11 is a common event in adenocarcinomas of the lung","volume":"62","author":"Sanchez-Cespedes","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.026_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1242\/dmm.004440","article-title":"Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy","volume":"3","author":"Contreras","year":"2010","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ejca.2022.05.026_bib26","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1038\/sj.onc.1210418","article-title":"Prevalence and specificity of LKB1 genetic alterations in lung cancers","volume":"26","author":"Matsumoto","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2022.05.026_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM198710083171504","article-title":"Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung","volume":"317","author":"Rodenhuis","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.026_bib29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.026_bib30","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/onc.2015.375","article-title":"Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma","volume":"35","author":"Schabath","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2022.05.026_bib31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.05.026_bib32","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2022.05.026_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.05.026_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/PAI.0b013e31826b128b","article-title":"Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer","volume":"21","author":"Liu","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ejca.2022.05.026_bib35","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3892\/or.2014.3432","article-title":"Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer","volume":"32","author":"Jiang","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2022.05.026_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjc.6604469","article-title":"Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients","volume":"99","author":"Koivunen","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.08.002","article-title":"LKB1\/STK11 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value","volume":"112","author":"Facchinetti","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","article-title":"STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive?","volume":"157","author":"Di Federico","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.05.026_bib39","unstructured":"Travis W, Brambilla E, Burke A, Marx A, Nicholson A. WHO classification of tumours of the lung, pleura, thymus and herat. vol. vol. 7. 4th ed. n.d.."},{"key":"10.1016\/j.ejca.2022.05.026_bib40","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"key":"10.1016\/j.ejca.2022.05.026_bib41","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2022.05.026_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000706","article-title":"STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort","volume":"5","author":"Papillon-Cavanagh","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.05.026_bib43","series-title":"Abstract CT084: relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC. Tumor Biology","first-page":"CT084","author":"Cho","year":"2020"},{"key":"10.1016\/j.ejca.2022.05.026_bib44","doi-asserted-by":"crossref","first-page":"23831","DOI":"10.18632\/oncotarget.6379","article-title":"Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer","volume":"8","author":"P\u00e9cuchet","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.05.026_bib45","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1038\/sj.onc.1207502","article-title":"Novel and natural knockout lung cancer cell lines for the LKB1\/STK11 tumor suppressor gene","volume":"23","author":"Carretero","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2022.05.026_bib46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/JTO.0000000000000056","article-title":"Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas","volume":"9","author":"Fang","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.05.026_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.05.026_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2019.01.003","article-title":"Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11","volume":"130","author":"La Fleur","year":"2019","journal-title":"Lung Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:04Z","timestamp":1760733424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"alternative-id":["S0959804922003057"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}